A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
Bicara Therapeutics
AstraZeneca
Endeavor Biomedicines, Inc.
EMD Serono
VM Oncology, LLC
EMD Serono